Market Closed -
BME
09:05:10 03/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
31.14
EUR
|
+0.71%
|
|
+7.53%
|
-24.20%
|
Fiscal Period: Marzo |
2020
|
2021
|
2022
|
2023
|
2025
|
2026
|
2027
|
---|
Capitalization
1 |
966.8
|
1,792
|
1,232
|
800.7
|
549.3
|
-
|
-
|
Enterprise Value (EV)
1 |
828
|
1,625
|
1,039
|
672
|
365.6
|
271.8
|
549.3
|
P/E ratio
|
6.98
x
|
19.3
x
|
25.1
x
|
737
x
|
12.1
x
|
6.29
x
|
4.22
x
|
Yield
|
1.15%
|
0.66%
|
-
|
-
|
1.58%
|
2.11%
|
-
|
Capitalization / Revenue
|
3.58
x
|
7.8
x
|
6.28
x
|
5.06
x
|
2.8
x
|
2.3
x
|
2.43
x
|
EV / Revenue
|
3.07
x
|
7.07
x
|
5.29
x
|
4.25
x
|
1.87
x
|
1.14
x
|
2.43
x
|
EV / EBITDA
|
5.07
x
|
16.6
x
|
20.8
x
|
322
x
|
4.22
x
|
2.07
x
|
15.3
x
|
EV / FCF
|
3
x
|
90.9
x
|
35.3
x
|
-22.9
x
|
5.47
x
|
2.72
x
|
-
|
FCF Yield
|
33.3%
|
1.1%
|
2.83%
|
-4.38%
|
18.3%
|
36.7%
|
-
|
Price to Book
|
-
|
10
x
|
5.56
x
|
4.03
x
|
2.34
x
|
1.92
x
|
-
|
Nbr of stocks (in thousands)
|
18,496
|
18,113
|
18,011
|
18,108
|
17,640
|
-
|
-
|
Reference price
2 |
52.27
|
98.95
|
68.42
|
44.22
|
31.14
|
31.14
|
31.14
|
Announcement Date
|
26/02/21
|
28/02/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: März |
2020
|
2021
|
2022
|
2023
|
2025
|
2026
|
2027
|
---|
Net sales
1 |
270
|
229.8
|
196.3
|
158.2
|
195.9
|
238.5
|
225.8
|
EBITDA
1 |
163.2
|
98.03
|
49.97
|
2.084
|
86.67
|
131.3
|
36
|
EBIT
1 |
155.9
|
92.45
|
44.07
|
-3.827
|
63.62
|
102.1
|
99.8
|
Operating Margin
|
57.77%
|
40.22%
|
22.45%
|
-2.42%
|
32.48%
|
42.81%
|
44.2%
|
Earnings before Tax (EBT)
1 |
145.6
|
95.13
|
43.79
|
-3.623
|
35.85
|
76.8
|
101.4
|
Net income
1 |
137.3
|
92.86
|
49.36
|
1.137
|
56.88
|
91.72
|
109.4
|
Net margin
|
50.85%
|
40.4%
|
25.14%
|
0.72%
|
29.03%
|
38.46%
|
48.43%
|
EPS
2 |
7.490
|
5.130
|
2.730
|
0.0600
|
2.572
|
4.952
|
7.380
|
Free Cash Flow
1 |
275.9
|
17.87
|
29.47
|
-29.4
|
66.8
|
99.75
|
-
|
FCF margin
|
102.21%
|
7.78%
|
15.01%
|
-18.59%
|
34.1%
|
41.83%
|
-
|
FCF Conversion (EBITDA)
|
169.13%
|
18.23%
|
58.97%
|
-
|
77.08%
|
75.95%
|
-
|
FCF Conversion (Net income)
|
201.03%
|
19.25%
|
59.71%
|
-
|
117.45%
|
108.75%
|
-
|
Dividend per Share
2 |
0.6000
|
0.6500
|
-
|
-
|
0.4925
|
0.6567
|
-
|
Announcement Date
|
26/02/21
|
28/02/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: March |
2021 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
98.69
|
45.25
|
85.89
|
34.94
|
30.19
|
65.13
|
18.71
|
54.94
|
33.98
|
46.21
|
80.19
|
37.45
|
40.51
|
33.33
|
44.6
|
38
|
36.3
|
EBITDA
1 |
40.57
|
12.49
|
44.82
|
20.6
|
11.31
|
31.94
|
12.56
|
5.436
|
-1.258
|
5.418
|
4.16
|
1.309
|
-3.385
|
-3.3
|
-
|
-
|
-
|
EBIT
1 |
37.95
|
-
|
43.36
|
19.01
|
9.829
|
28.84
|
11.86
|
3.372
|
-2.572
|
4.047
|
1.475
|
-0.184
|
-5.118
|
-3.467
|
0.3
|
-2
|
-8.6
|
Operating Margin
|
38.45%
|
-
|
50.48%
|
54.42%
|
32.55%
|
44.28%
|
63.38%
|
6.14%
|
-7.57%
|
8.76%
|
1.84%
|
-0.49%
|
-12.63%
|
-10.4%
|
0.67%
|
-5.26%
|
-23.69%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-
|
11.99
|
32.61
|
14
|
-2.821
|
-3.217
|
4.497
|
-
|
1.57
|
-6.473
|
-1.1
|
0.3
|
-2
|
-8.4
|
Net income
1 |
43.2
|
11.5
|
38.16
|
22
|
12.95
|
34.92
|
8.477
|
5.984
|
1.411
|
5.024
|
6.435
|
1.521
|
-6.819
|
-3.233
|
0.4
|
-2.3
|
-9.5
|
Net margin
|
43.78%
|
25.41%
|
44.43%
|
62.97%
|
42.88%
|
53.62%
|
45.32%
|
10.89%
|
4.15%
|
10.87%
|
8.02%
|
4.06%
|
-16.83%
|
-9.7%
|
0.9%
|
-6.05%
|
-26.17%
|
EPS
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.0700
|
0.0200
|
-0.1100
|
-0.4500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/07/21
|
28/10/21
|
28/02/22
|
28/04/22
|
27/07/22
|
27/07/22
|
27/10/22
|
28/02/23
|
26/04/23
|
27/07/23
|
27/07/23
|
26/10/23
|
28/02/24
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2025
|
2026
|
2027
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
139
|
167
|
193
|
129
|
184
|
278
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
276
|
17.9
|
29.5
|
-29.4
|
66.8
|
99.8
|
-
|
ROE (net income / shareholders' equity)
|
241%
|
66.2%
|
24.6%
|
0.55%
|
28.9%
|
31.6%
|
-
|
ROA (Net income/ Total Assets)
|
60.3%
|
26.6%
|
13%
|
-
|
15.5%
|
23.4%
|
-
|
Assets
1 |
227.5
|
349.3
|
380.8
|
-
|
366.9
|
392
|
-
|
Book Value Per Share
2 |
-
|
9.850
|
12.30
|
11.00
|
13.30
|
16.20
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
3
|
7.8
|
8.85
|
16
|
9.4
|
10.5
|
16
|
Capex / Sales
|
1.11%
|
3.4%
|
4.51%
|
10.09%
|
4.8%
|
4.4%
|
7.09%
|
Announcement Date
|
26/02/21
|
28/02/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Last Close Price
31.14
EUR Average target price
49.2
EUR Spread / Average Target +58.00% Consensus |
1st Jan change
|
Capi.
|
---|
| -24.20% | 592M | | +1.45% | 40.51B | | -15.94% | 31.67B | | +52.66% | 24.62B | | -14.50% | 15.65B | | -14.38% | 12.07B | | -9.12% | 11.97B | | -42.56% | 11.61B | | +4.87% | 8.81B | | -4.33% | 8.5B |
Biopharmaceuticals
|